Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4601 to 4650 of 8238 results

  1. Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received radiotherapy (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Recommendation ID NG162/1 Question Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are

  2. Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had radiotherapy less recently?

    Recommendation ID NG162/2 Question Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy

  3. Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?

    Recommendation ID NG161/2 Question Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who

  4. Prophylactic antibiotics for respiratory disorders:- Are prophylactic antibiotics clinically and cost effective in the management of respiratory symptoms in adults with cerebral palsy with significant respiratory comorbidity?

    Recommendation ID NG119/4 Question Prophylactic antibiotics for respiratory disorders:- Are prophylactic antibiotics clinically and cost

  5. Are psychological interventions effective for treating moderate to severe anxiety disorders (including obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social anxiety disorder) in pregnancy?

    Recommendation ID CG192/5 Question Are psychological interventions effective for treating moderate to severe anxiety disorders (including

  6. Are psychosocial interventions clinically and cost effective when compared with standard care for people with psychosis and coexisting substance misuse?

    Recommendation ID CG120/6 Question Are psychosocial interventions clinically and cost effective when compared with standard care for people

  7. Standardised criteria for hospital discharge:- Are standardised criteria for hospital discharge clinically and cost effective in specific medical emergencies? [See the evidence review on standardised discharge criteria.]

    Recommendation ID NG94/14 Question Standardised criteria for hospital discharge:- Are standardised criteria for hospital discharge clinically

  8. Are the Department of Health's 'Let's get moving' physical activity care pathway and the general practice physical activity questionnaire (GPPAQ) both commonly used in primary care? How do primary care practitioners view GPPAQ and, if they do not use it, why not?

    Recommendation ID PH44/7 Question Are the Department of Health's 'Let's get moving' physical activity care pathway and the general practice

  9. Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational diabetes?

    Recommendation ID NG3/5 Question Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that

  10. Step 1 treatment: Are there subgroups of people with hypertension who should start on dual therapy?

    Recommendation ID NG136/04 Question Step 1 treatment: Are there subgroups of people with hypertension who should start on dual therapy

  11. What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared with other psychological therapies in children aged 5 to 11 years and young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/5 Question What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural

  12. Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual care/advice for children with faltering growth?

    Recommendation ID NG75/3 Question Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual

  13. Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps, leaflets and messaging) help dental teams to provide people with support to improve their oral health?

    Recommendation ID NG30/3 Question Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps

  14. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

    Recommendation ID IPG669/1 Question Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

  15. Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic acid given indefinitely compared with zoledronic acid given for a fixed duration in patients with myeloma?

    Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic

  16. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    Recommendation ID CG148/4 Question Bladder management strategies:- What are the long-term risks and effects on quality of life of different

  17. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    Recommendation ID CG146/4 Question Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of

  18. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...

  19. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

  20. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe

  21. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in

  22. Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for clinical trials of management of Lyme disease?

    Recommendation ID NG95/1 Question Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for

  23. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    Recommendation ID NG14/02 Question Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment

  24. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    Recommendation ID NG14/01 Question Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response

  25. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    Recommendation ID NG119/3 Question Detection and management of respiratory disorders in primary and community care:- Can detection and

  26. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    Recommendation ID CG191/4 Question Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum

  27. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    Recommendation ID NG196/7 Question Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people

  28. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory

  29. Weight loss for managing pelvic floor dysfunction: Can weight loss reduce symptoms of pelvic floor dysfunction in women who are overweight or obese?

    Recommendation ID NG210/11 Question Weight loss for managing pelvic floor dysfunction: Can weight loss reduce symptoms of pelvic floor

  30. What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Recommendation ID CG173/3 Question What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia

  31. Carbamazepine for treating trigeminal neuralgia:- What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Recommendation ID CG173/3 Question Carbamazepine for treating trigeminal neuralgia:- What is the clinical and cost effectiveness of carbamazepine

  32. The evidence on cardiac contractility modulation device implantation for heart failure raises no major safety concerns. However, the evidence on efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of  research .

    Recommendation ID IPG655 Question The evidence on cardiac contractility modulation device implantation for heart failure raises no major

  33. Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service more clinically and cost effective for managing stable angina than current clinical practice?

    Recommendation ID CG126/4 Question Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service

  34. What is the utility of routine cardiovascular evaluation for asymptomatic people with FH?

    Recommendation ID CG71/6 Question What is the utility of routine cardiovascular evaluation for asymptomatic people with FH? Any

  35. Audit:- What is the clinical and cost effectiveness of collecting long-term outcomes in a national trauma audit system?

    Recommendation ID NG40/1 Question Audit:- What is the clinical and cost effectiveness of collecting long-term outcomes in a national trauma

  36. Augmentative and alternative communication:- What is the current pattern of provision and use of augmentative and alternative communication (AAC) by people with motor neurone disease (MND) in England?

    Recommendation ID NG42/6 Question Augmentative and alternative communication:- What is the current pattern of provision and use of augmentative

  37. Awareness raising:- What is the effectiveness and cost effectiveness of different methods of awareness raising about air pollution (including air pollution alerts) on people's behaviour and on acute and chronic health outcomes?

    Recommendation ID NG70/5 Question Awareness raising:- What is the effectiveness and cost effectiveness of different methods of awareness

  38. Long-term risk of renal scarring and impaired renal function: A well designed cohort study investigating long-term outcomes including renal scarring and renal function of children who have had UTI should be conducted in the UK.

    Recommendation ID NG224/02 Question Long-term risk of renal scarring and impaired renal function: A well designed cohort study investigating

  39. Barriers and facilitators:- What are the barriers and facilitators for young people and adults with coexisting severe mental illness and substance misuse to obtain an optimal service (including optimal time frame for delivering interventions) to meet their needs and enable their recovery?

    Recommendation ID NG58/4 Question Barriers and facilitators:- What are the barriers and facilitators for young people and adults with coexisting

  40. Prevention of prolonged pregnancy: Based on individual patient data meta-analysis, what is the optimal timing of induction of labour?

    Recommendation ID NG207/02 Question Prevention of prolonged pregnancy: Based on individual patient data meta-analysis, what is the optimal

  41. Use of routinely collected real-world data to examine the effectiveness and cost effectiveness of continuous glucose monitoring: Based on routinely collected real-world data, what is the effectiveness and cost effectiveness of CGM devices to improve glycaemic control?

    Recommendation ID NG17/03 Question Use of routinely collected real-world data to examine the effectiveness and cost effectiveness of continuous